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ABSTRACT 
BACKGROUND: The number of people living with previous hepatitis-C infection that have attained 
a sustained viral response (SVR) is expected to grow rapidly. So far, the prognosis of this group 
relative to the general population is unclear.  
METHODS: Individuals attaining SVR in Scotland in 1996-2011 were identified using a national 
database. Through record-linkage, we obtained cause-specific mortality data complete to Dec 2013. 
We calculated standardised-mortality-ratios (SMRs) to compare the frequency of mortality in SVR 
patients to the general population. In a parallel analysis, we used Cox regression to identify 
modifiable patient characteristics associated with post-SVR mortality.  
RESULTS: We identified 1824 patients, followed on average for 5.2 years after SVR. In total, 78 
deaths were observed. Overall, all-cause mortality was 1.9 times more frequent for SVR patients than 
the general population (SMR: 1.86; 95% CI:1.49-2.32). Significant cause-specific elevations were 
seen for death due to primary liver cancer (SMR: 23.50; 95% CI:12.23-45.16), and death due to drug-
related causes (SMR: 6.58, 95%CI:4.15-10.45). Together these two causes accounted for 66% of the 
total excess death observed. All of the modifiable characteristics associated with increased mortality 
were markers either of heavy alcohol use or injecting drug use. Individuals without these behavioural 
markers (32.8% of cohort) experienced equivalent survival to the general population (SMR: 0.70; 
95% CI:0.41-1.18) 
CONCLUSIONS:  
Mortality in Scottish SVR patients is higher overall than the general population. The excess was 
driven by death from drug-related causes and liver cancer. Health risk behaviours emerged as 
important modifiable determinants of mortality in this population.  
LAY SUMMARY:  
Patients cured of hepatitis C through treatment had a higher mortality rate overall than the general 
population. Most of the surplus mortality was due to drug-related causes and death from liver cancer. 
A history of heavy alcohol use and injecting drug use were associated with a higher mortality risk. 
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INTRODUCTION:  
The use of direct acting antiviral drugs has led to vast improvements in the efficacy and tolerability of 
treatment for chronic hepatitis C virus (HCV) infection. [1,2] As a result, the number of previously-
infected persons living with a sustained viral response (SVR) is likely to increase rapidly in the years 
ahead. It is important therefore to gain a better understanding of what an SVR means in terms of an 
individual’s subsequent health. SVR is regarded as a “cure” by clinicians[3]; patients[4]; 
pharmaceutical companies [5,6]; and the lay media[7]. Whilst this is accurate in virological terms (i.e. 
SVR does represent a durable eradication of the virus from blood serum[8]), the extent to which SVR 
is a cure for other noted aspects of the hepatitis C condition – namely: liver fibrosis[9], hepatocellular 
carcinoma[10], increased all-cause mortality relative to the general population [11] and extrahepatic 
manifestations[12] - remains unclear. The object of this study was to evaluate the mortality rate aspect 
of this knowledge gap. Although we know that SVR patients have lower mortality rates than non-
SVR patients [3, 13] we do not know how the mortality of this group compares to the general 
population. This is in contrast with other fields of medicine, such as oncology, where comparing 
patient survival against the general population is central to determining rates of cure [14, 15] 
Thus far, only two studies have compared mortality in SVR patients to the general population. The 
first study was based on 192 SVR patients recruited from five tertiary liver clinics in Europe and 
Canada. [16] All patients had advanced fibrosis at baseline and the average age was 49 years. For this 
cohort, ten year survival - at 91.1% - was no different to survival in the general population. More 
recently, Bruno et al examined survival in 181 SVR patients recruited from five clinics in Italy.[17] 
All individuals in this cohort had compensated cirrhosis at baseline, and the average age was 59 years. 
Here too, ten year survival -at 90.9% - was comparable to the general population. These initial data 
are encouraging, nevertheless a question mark remains over how representative their findings are to 
the wider SVR population. Firstly because both studies were confined to patients with advanced 
fibrosis and did not include patients with milder disease (i.e. the group where the greatest burden of 
infection lies [18]). Secondly, because patients in both studies were recruited from potentially select 
clinics that may not be representative –either in terms of the patient case mix or the clinical care 
received – of all clinics administering therapy. Therefore, in this study we analysed mortality data 
from a large nationwide cohort of SVR patients in Scotland. Our objective was to compare cause-
specific mortality in SVR patients to the underlying general population.  
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METHODS: 
1. DATA SOURCES 
1.1:  DATA ON CAUSE-SPECIFIC MORTALITY RATES IN SVR PATIENTS 
We used data from a previously-described [19] retrospective cohort of HCV infected patients treated 
in Scotland who began and terminated a course of interferon-based antiviral therapy between Jan 
1996 and Dec 2010, respectively. This cohort was restricted to patients who were treatment-naïve, and 
who at the time of treatment, had compensated liver disease. It further excluded individuals with HIV 
or hepatitis B co-infection (the latter was inferred on the basis of surface antigen positivity). In total, 
3385 individuals met these criteria of whom 1824 attained SVR and form the focus of this present 
analysis. Subsequent mortality data, specifically information on the date and the cause of death, were 
obtained through record linkage to the Scottish mortality register -see [16] for further details. We 
examined the following seven causes of death; death due to: (i) primary liver cancer, (ii) other liver 
disease (i.e. liver death not due to primary liver cancer), (iii) drug-related causes, (iv) external causes 
(referring mainly to death from accidents, homicide, and suicide), (v) all non-liver cancers, (vi) 
diseases of the circulatory system, (vii) and all other causes not listed above. We used the 
International Classification of Disease (ICD) code present in the underlying cause of death field to 
define these mortality categories; see eTable 1 for further details. Mortality rates were expressed in 
terms of person-years of follow-up. For each individual, we commenced follow-up at 9 months after 
antiviral treatment was stopped (thereby factoring in 6 months for SVR eligibility and a further 3 
month grace period to physically receive the requisite SVR test), and ended follow-up at the date of 
mortality, or the date that our extract of the mortality register was complete until (31 Dec 2013).  
1.2: DATA ON CAUSE-SPECIFIC MORTALITY RATES IN THE GENERAL POPULATION 
We obtained a bespoke dataset from the General Registry Office Scotland of all deaths occurring in 
Scotland between 1996 and 2014, according to the underlying cause of death, the age at death, the 
calendar year of death, and the decedent’s gender. We linked this dataset to mid-year Scottish 
population estimates to determine cause-specific mortality rates for the general population. We 
examined the same seven causes of death as for our SVR cohort and again used the ICD code present 
in the underlying cause of death field to define these categories (see eTable 1).  
2: STATISTICAL ANALYSIS: 
2.1: SURVIVAL IN SVR PATIENTS RELATIVE TO THE GENERAL POPULATION  
2.1.1: TEN YEAR SURVIVAL FUNCTION 
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We calculated the Kaplan Meier survival function up to ten years after SVR, and juxtaposed this 
against the survival function for the general population according to the equivalent age, sex and 
calendar year distribution.  We generated these curves both in relation to the total cohort (N=1824), 
and also specifically for SVR patients who had not received a diagnosis of cirrhosis at baseline 
(N=1717).Our rationale for focusing on this latter subgroup was that non-cirrhotic SVR patients tend 
to be discharged from clinical care and their liver-related mortality should be low.  
2.1.2: STANDARDISED MORTALITY RATIOS 
The SMR represents the ratio of the number of expected deaths (i.e. expected given general 
population mortality rates) to the number of observed deaths. We determined the standardised 
mortality ratio (SMR) adjusted for age, gender and calendar year. We calculated the SMR for all-
cause mortality, as well as the SMR for each of the seven causes of death listed afore. As per our 
estimates of ten year survival, SMRs were determined both for all SVR patients, and also specifically 
for SVR patients who had not received a diagnosis of cirrhosis at baseline.  
2.2 IDENTIFYING BASELINE FACTORS ASSOCIATED WITH POST-SVR MORTALITY  
We used Cox regression to identify baseline patient characteristics associated with post-SVR 
mortality. The baseline factors we assessed were: (i) age group (<35yrs; 35-49 yrs; and 50yrs+); (ii) 
gender; (iii) diagnosis of liver cirrhosis; (iv) Charlson comorbidity index (CCI); (v) genotype; (vi) 
maximum alcohol consumption sustained for at least six months; (vii) intravenous drug use history; 
(viii) past hospitalisation for alcohol intoxication; (viiii) past hospitalisation for violence-related 
injury; (x) past hospitalisation for drug intoxication; (xi) pre-treatment aspartate aminotransferase-to-
platelet-ratio index(APRI); and (xii) pre-treatment gamma glutamyl transferase(GGT). Diagnosed 
liver cirrhosis refers to whether the patient had been diagnosed with liver cirrhosis by the time of SVR 
attainment. Diagnosis of liver cirrhosis in Scotland over this study period was made through a 
combination of biopsy; transient elastography; abdominal ultrasound; clinical examination; and 
routine liver function tests. Intravenous drug use history and maximum alcohol consumption were 
determined from data self-reported by the patient at the time of their liver clinic assessment. 
Maximum alcohol consumption was specifically defined as the highest level of alcohol use, sustained 
for six months or more, prior to being seen at the HCV treatment clinic. This was categorised as <21 
units/week; 22-49 units/week and ≥50 units/week. Past hospitalisation for alcohol intoxication, 
violence-related injury and drug intoxication were determined from historical hospitalisation records 
dating back to Jan 1980. The ICD codes used to define these events are listed in eTable 2. We 
calculated the CCI to gauge each patient’s comorbidity burden at baseline.[20] The CCI assigns a 
score of 1-6 for each comorbidity present, with a higher score denoting greater severity: A metastatic 
solid tumour, for example, carries a score of 6, renal disease carries a score of 2, whereas 
uncomplicated diabetes incurs a score of 1. The final CCI for an individual is the total of these scores. 
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We used historical hospitalization data dating back to January 1, 1980 to determine the 
presence/absence of the various comorbidities at baseline (as per the ICD codes set out by Quan et al 
[21]). We extracted all liver function tests recorded on the clinical database within 2 years of starting 
treatment. We calculated the mean aspartate aminotransferase level and mean platelet count in order 
to infer the APRI. We categorised APRI as <0.7 and ≥0.7 corresponding to the optimal cut off  to 
distinguish individuals with mild fibrosis (i.e. Metavir F0-F1) from individuals with non-mild fibrosis 
(i.e. Metavir F2+) [22]. We further determined the mean level of GGT, given that this was previously 
found to be an important determinant of SVR attainment in Scotland. [23] Associations between these 
12 baseline factors and all-cause mortality were calculated initially both in their crude unadjusted 
forms, and after adjustment for age group, gender, cirrhosis and CCI. As with our SMR analysis, 
associations were calculated separately both for all SVR patients, as well as specifically for SVR 
patients without a diagnosis of cirrhosis at baseline.   
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RESULTS: 
1: DESCRIPTION OF THE SVR PATIENTS AT BASELINE: 
In this cohort of 1824 SVR patients, the mean age was 40.7 years and most individuals were male 
(67.9%) - see Table.1. The median calendar period at baseline was 2008 (IQR:2006-2010). All 
patients had compensated liver disease. Liver cirrhosis was diagnosed in 5.8%, and 53.6% had an 
APRI score <0.7 (indicative of Metavir F0-F1) where this score was known. In terms of health risk 
behaviours, almost a fifth (18.1%) had a history of heavy alcohol use, and 58.6% reported ever 
injecting drugs. Further, 6.9%, 17.6% and 14.3% had a history of previous hospitalisation due to 
alcohol intoxication, violence-related injury and drug intoxication, respectively. A description of the 
overlap between health risk behaviour variables is provided in eTable 3.     
2: MORTALITY EVENTS OCCURING AFTER SVR: 
The total duration of follow up in our cohort was 10,915 person-years. The mean and median duration 
of follow-up time per patient was 5.2 years and 5.9 years, respectively. In all, 78 deaths were 
observed. Nine deaths were due to primary liver cancer (eight deaths of which were cases of 
hepatocellular carcinoma, and one was a case of intrahepatic bile duct cancer); seven deaths were due 
to other liver-related causes; 18 deaths were drug-related; 5 deaths were due to external causes; 16 
deaths were from non liver cancers; 9 deaths were due to diseases of the circulatory system; and the 
remaining 14 deaths were from other causes. To note, lung cancer was the most common type of non-
liver cancer death (N=7), whilst chronic obstructive pulmonary disease was the most common type of 
“other” death (N=4). Finally, the nine deaths from primary liver cancer occurred after a mean of 4.8 
years of follow-up at ages ranging from 46-77 years.  
3: SURVIVAL IN SVR PATIENTS RELATIVE TO THE GENERAL POPULATION  
3.1: TEN YEAR SURVIVAL FUNCTION 
For all SVR patients, ten year survival was 93.2% (95% Cl: 91.2%-84.8%) versus 96.1% for the 
general population. For SVR patients without baseline cirrhosis, ten year survival was 94.6% (95% 
CI: 92.7 96.1), versus 96.3% for the general population (Fig.1).   
3.2: ALL-CAUSE AND CAUSE-SPECIFIC STANDARDISED MORTALITY RATIOS: 
The number of all-cause deaths that would have been expected in our SVR cohort given general 
population mortality rates was 42. Thus with 78 deaths actually observed, the overall SMR was 1.86 
(95% CI: 1.49-2.32). When confining the analysis to patients that had not been diagnosed with liver 
cirrhosis at baseline, the SMR fell to 1.55 (95% CI: 1.20-2.01). In terms of cause-specific SMRs (see 
Table 2.), significant elevations were observed for death due to primary liver cancer and death due to 
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drug-related causes. The SMR for liver cancer was less pronounced in the subgroup of patients 
without diagnosed cirrhosis at baseline (SMR: 9.02; 95% CI: 2.91-27.96), than in the entire SVR 
cohort as a whole (SMR: 23.50; 95% CI: 12.23-45.16). In contrast, the SMR for drug related mortality 
was comparable between all SVR patients (SMR: 6.58, 95% CI: 4.15-10.45), and SVR patients 
without baseline cirrhosis (SMR: 6.90, 95% CI: 4.35-10.96).  We did not see any statistically 
significant differences in the SMRs for liver cancer mortality, all-cause mortality and drug mortality 
according to age (see Figure 3[i]). Finally, no statistically significant elevations were noted for the 
remaining cause-specific categories, including: other liver disease; external causes, diseases of the 
circulatory system; and non-liver cancers.  
4: THE ABSOLUTE CONTRIBUTION OF EACH CAUSE TO THE OVERALL EXCESS:  
Drug-related mortality made the biggest absolute contribution to overall excess mortality (42% in all 
SVR patients, and 75% in SVR patients without baseline cirrhosis). Primary liver cancer accounted 
for 24% of the total excess in all SVR patients and 13% of the excess in SVR patients without 
cirrhosis. Taken together, these two causes of death accounted for 66% of all excess deaths in the 
SVR cohort as a whole, and 88% of all excess death in SVR patients without cirrhosis (see Fig.2). We 
further examined the absolute contribution of primary liver cancer and drug-related mortality in all 
SVR patients according to age during follow-up (see Figure 3[ii]). In the under 50s, drug-related 
causes accounted for the majority of the excess death (53%), whilst the contribution of primary liver 
cancer was minimal (<5%). Conversely, in the over 50s, most of the excess (54%) was due to liver 
cancer, whilst drug-related mortality played a more minor role (accounting for only 26% of the 
excess).  
5: BASELINE FACTORS ASSOCIATED WITH ALL-CAUSE MORTALITY 
Ten factors were significantly associated (p<0.05) with an increased risk of post-SVR mortality 
following adjustment for age group and gender, cirrhosis and CCI; see Table.1. These were as 
follows: older age; male gender; diagnosis of liver cirrhosis; high Charlson comorbidity score; past 
alcohol consumption ≥50+ units/wk sustained for six months or more; history of intravenous drug 
use; past hospitalisation for alcohol intoxication; past hospitalisation for drug intoxication; and past 
hospitalisation for violence-related injury, and APRI <0.7. 
6: POST-HOC ANALYSES: GENERATING A COMPOSITE SCORE FOR HEALTH RISK 
BEHAVIOURS 
The five modifiable factors associated with post-SVR mortality were as follows: 1. past alcohol 
consumption ≥50+ units/wk sustained for six months or more; 2. history of intravenous drug use; 3. 
past hospitalisation for alcohol intoxication; 4. past hospitalisation for drug intoxication; and 5.past 
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hospitalisation for violence-related injury heavy alcohol use). In a post-hoc analysis, we generated a 
4-point composite score based on the presence or absence of these five factors (see Fig.4). The 
intention was to create a proxy marker for health risk behaviours present during follow-up. We 
calculated SMRs for all-cause mortality according to this composite score and observed a strong dose-
response relationship (p-value for trend, <0.001). Among all SVR patients with a score of zero (i.e. 
indicating the minimum level of health risk behaviour), the SMR was 0.70 (95% CI: 0.41-1.18), 
whereas for individuals with a score of 3 (i.e. the maximum score, indicating the highest level of 
health risk behaviour), the SMR was 6.19 (95% CI: 3.60-10.67). We also constructed a multivariate 
Cox regression model to assess the association between our behaviour score and the mortality hazard 
after adjusting for age, sex, cirrhosis, CCI and APRI (see Table 3). We observed a stepwise change in 
the mortality hazard according to behaviour score. Among all SVR patients, the hazard was 2.12 
times (p=0.035) , 4.25 times (p<0.001), and 7.28 times (p<0.001) higher for individuals with a score 
of 1, 2 and 3, respectively, relative to individuals with a score of zero.  
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DISCUSSION: 
MAIN FINDINGS:  
The arrival of highly effective and tolerable antiviral regimens for chronic hepatitis C infection has set 
the stage for a rapid increase in the number of persons living with SVR. Yet, our present 
understanding of the prognosis that this “cured” population face is incomplete. Although we know 
that SVR patients exhibit superior mortality and morbidity rates relative to non-SVR patients [3, 13, 
18], we know little about how these rates compare to the broader general population. In the present 
study, we followed 1824 SVR patients up for 5.2 years on average, and observed mortality rates in 
excess of the general population.  Specifically, among all SVR patients, mortality rates were almost 2-
fold higher (SMR: 1.86; 95% CI: 1.49-2.32), whilst among SVR patients without a diagnosis of 
cirrhosis at baseline - a group who on the whole will tend to be discharged from specialist care 
without further follow-up - mortality rates were 1.6-fold higher (SMR: 1.55; 95% CI:1.20-2.01) .  Our 
cause-specific analyses (see Table 2 and Fig.2-3) demonstrated two important points. Firstly, that the 
overall excess was driven, in the main, by a higher than expected frequency of death from liver cancer 
and death from drug-related causes. Secondly, that the contribution of these two causes differed with 
respect to age. Drug-related mortality accounted for 53% of all excess death in the under 50s (in 
comparison, only 4.3% of the excess death was due to primary liver cancer). Conversely, death from 
liver cancer accounted for 54% of all excess death in the over 50s (whereas, in this age group, only 
26% of the excess death was due to drug-related causes).  
THE OCCURRENCE OF PRIMARY LIVER CANCER: 
The largest cause-specific SMRs were seen with respect to primary liver cancer. In our SVR cohort as 
a whole, the risk of dying from liver cancer was more than 20 times greater than the general 
population (SMR: 23.50; 95% CI: 12.23-45.16). Notably, an excess risk of dying from liver cancer 
remained - SMR: 9.02; 95% CI: 2.91-27.96 - after excluding individuals with diagnosed liver 
cirrhosis at baseline. This result requires careful interpretation. On the one hand, it could lend support 
to previous observations that the risk of liver cancer after SVR is not confined to cirrhotic patients, 
but extends more widely to some patients at the pre-cirrhosis stage.[24-28] Alternatively, it may 
reflect a high level of undiagnosed liver cirrhosis in our cohort (indeed, the potential for this is 
appreciable, given that the majority of patients had no record of a liver biopsy or fibroscan being 
conducted  in the two years prior to baseline – see eTable 4). To inform which interpretation is more 
valid, we reviewed the medical notes of the three “non cirrhotic” individuals who went on to develop 
primary liver cancer (involving two deaths from hepatocellular carcinoma and one from intrahepatic 
bile duct carcinoma). While two patients had indications of significant/severe fibrosis, none of the 
three would have met the definition of compensated cirrhosis currently adopted by NHS England (see 
Appendix A), despite all having the requisite tests to do so on at least one level (i.e. all three had an 
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APRI score and AST:ALT ratio pre-treatment; while one case had an ultrasound and another had a 
biopsy upon completion of therapy). Further, only one case was retained in on-going clinical follow-
up post SVR, while the other two were discharged. More research is arguably needed to inform which 
SVR patients can be safely discharged, versus which patients would benefit from regular HCC 
screening. However, we must stress that although the relative risk of a liver cancer death was high in 
the non-cirrhotic group (i.e.  nine times higher relative to the general population), the absolute risk – 
both of liver cancer and indeed of any liver-related event - was still very low (<1% after 7.5 years - 
see eFig.1).  
PATIENT CHARACTERISTICS ASSOCIATED WITH POST-SVR MORTALITY: 
To understand how the elevated mortality rate in “cured” hepatitis C patients might be reversed, we 
carried out a regression analysis to identify modifiable predictors of all-cause mortality (see Table.1). 
Ten predictive characteristics were identified in total, of which half – older age, male gender, liver 
cirrhosis; high CCI; and APRI <0.7 – were non-modifiable. But the remaining characteristics 
identified were markers of health risk behaviours (history of injecting drug use, history of heavy 
alcohol use, and past hospitalisation for violence, drug intoxication or alcohol intoxication) that, in 
principle at least, can be reversed. We created a composite score to approximate the degree of health 
risk behaviours present during follow-up (see Fig.4). The strong correlation between this composite 
score and the all-cause SMR suggests two things. Firstly, that health risk behaviours exert a strong 
influence on the extent to which mortality exceeds general population levels. Secondly, where health 
risk behaviours are minimal (i.e. as indicated by a score of zero) all-cause mortality rates are 
equivalent to and even lower than the general population.  
From the non-modifiable predictors identified in this study, the increased mortality risk associated 
with APRI <0.7 (versus APRI ≥0.7) was unexpected and at first glance paradoxical – see Table 1. 
Subsequent interrogation revealed however that this association was very cause-specific, being driven 
only by an increased risk for drug mortality (see eFig.2). The association overall therefore is probably 
due to residual confounding. Mild disease will be associated with more recent acquisition of HCV 
(given that fibrosis increases with duration of infection), which in turn will be associated with active 
drug use. With more robust data on active drug use at baseline, we would therefore not expect an 
association with APRI<0.7 to persist. 
CONSISTENCY WITH PREVIOUS WORK: 
Our finding of higher mortality in SVR patients relative to the general population is not supported by 
two previous studies. In a cohort of 192 SVR patients with F3-F4 fibrosis and an average age of 49 
years, Van der Meer et al observed a 10-year survival rate of 91.1%. [17] This was on par with 
survival in the general population. More recently, Bruno et al reported 10 year survival of 90.9% for 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
177 SVR cirrhotic patients with a mean age of 59 years. [18] Again, this 10-year survival was 
comparable to the general population. In contrast, for the present study, we followed up a much larger 
(N=1824), younger (mean age of 40.7 yrs) and more inclusive (comprising patients across the fibrosis 
continuum – not just those at an advanced end) group of SVR patients. Conversely, the 10-year 
survival that we observed of 93.2% was significantly lower than the 96.2% survival expected for the 
general population taking age, sex and calendar period into account. In overall terms, 86% more 
deaths were observed during our study than would have been expected under general population 
mortality rates (i.e. 78 deaths observed versus 42 expected). One possible explanation for the higher 
mortality rate in our study could be selection bias. The patients in our Scottish cohort represent the 
vast majority (80%+)  of individuals attaining SVR in Scotland over the 1996-2011 time frame of this 
study. In contrast, the two previous studies were largely made up of individuals with biopsy-proven 
advanced liver fibrosis that attended a small number of tertiary clinics that may not accurately reflect 
the wider SVR population. Clearly more studies, from a variety of cohorts, are required to form a 
complete picture on this issue. Otherwise, our results concur with a prior analysis from Scotland 
reporting increased hospitalisation rates in SVR patients relative to the general population [29]. Our 
results are also consistent with a nationwide cohort study from Denmark. [30] In this study, Omland 
et al observed that individuals who clear HCV infection spontaneously (not via treatment albeit) had 
higher overall mortality than the general population. However, - in line with this study (see fig.4) - 
mortality was more comparable to the general population in subgroups without a history of alcohol 
and drug abuse.   
LIMITATIONS OF THIS STUDY: 
There are several limitations in this analysis to highlight. Cirrhosis was diagnosed in only 5.8% of 
patients at baseline, however due to inadequate testing, this is likely to be an underestimate of the true 
fraction with cirrhosis. Indeed, e-Table 4 shows that only 44% of patients received a liver biopsy or a 
fibroscan in the two years prior to SVR attainment, which highlights the lack of uniform cirrhosis 
surveillance in our cohort. Potentially, undiagnosed liver cirrhosis could explain why we observed six 
liver deaths in our non-cirrhotic group, albeit we think that this is unlikely because when we reviewed 
the medical notes of the 3 “non-cirrhotic” patients who developed liver cancer, we did not find 
anything to suggest that these individuals were cirrhotic in reality. Another limitation is that we had 
no information on the socioeconomic status of patients in this cohort. Because hepatitis C virus 
infection disproportionately affects people of lower socioeconomic status, and lower socioeconomic 
status is in turn associated with higher mortality rates [31], the omission of this variable could have 
inflated our survival differences. Thirdly, our data on health risk behaviours are limited in that they 
relate only to the baseline time point, and mostly focus on only the extremes of alcohol and drug use. 
Future studies correcting for these weaknesses and additionally examining the impact of other major 
health behaviours –tobacco smoking, physical activity and diet—would be valuable. Fourthly, 
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patients in our cohort were treated with either standard interferon ± ribavirin, or pegylated interferon ± 
ribavirin. These regimens are long (16-48 weeks) and entail significant adverse effects. As a result, 
patients would typically have received intensive coaching from clinicians and nursing staff (and this 
coaching would have applied especially to SVR patients who, given futility stopping rules, remain in 
the treatment window for longer than non-SVR patients). We have previously speculated that this 
coaching and/or the euphoria of attaining SVR may have an important galvanising effect on patients 
with regard to encouraging more salubrious health behaviours [19]. Thus, in the impending era of 
highly tolerable, accessible and efficacious antiviral therapy– i.e. an era that will obviate the same 
level of patient coaching and patient commitment – a very different post-SVR picture could emerge. It 
will be important to repeat this analysis five years hence. Finally, we did not have robust data on 
diabetes mellitus status and obesity despite these conditions being recognised determinants of liver 
sequelae in the SVR population.[32] 
SUMMARY: 
In this large nationwide Scottish cohort, mortality in patients with a hepatitis C “cure” was higher than 
the general population.  The excess was mainly driven by death from liver cancer and death from 
drug-related causes. Health risk behaviours emerged as the major modifiable risk factor for mortality 
in this population underlining the importance of a multidisciplinary approach to HCV that addresses 
lifestyle risk factors in addition to viral infection. On this note the SVR time-point may be a 
particularly opportune moment to assess what other services and support the patient may be in need 
of. To minimise the post-SVR risk of HCC, careful and prudent staging of liver fibrosis should be 
performed prior to discharge to identify those patients who might benefit from regular screening. 
Arguably, more research is needed to bottom out more precisely which SVR patients stand to benefit 
from such surveillance. As a final aside, this analysis has bearing on the new WHO targets to cut 
global death from hepatitis B and C by 10% before 2020, and by 65% by 2030 [33].  
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FIGURE LEGENDS:  
Fig.1: Ten-year survival relative to the general population for: (i) all SVR patients; and (ii) SVR 
patients without cirrhosis. 
Fig.2: Absolute contribution (%) to the overall excess for each cause of death, for (i) all SVR patients, 
and (ii) SVR patients without cirrhosis at baseline. 
Fig.3: For all SVR patients: (i) cause-specific standardised mortality ratios according to age, and (ii) 
absolute contribution (%) to the overall excess for each cause of death, according to age. 
Fig.4: Standardised mortality ratio according to baseline health risk behaviours, for (i) all SVR 
patients, and (ii) SVR patients without cirrhosis.  
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ABSTRACT 
BACKGROUND: The number of people living with previous hepatitis-C infection that have attained 
a sustained viral response (SVR) is expected to grow rapidly. So far, the prognosis of this group 
relative to the general population is unclear.  
METHODS: Individuals attaining SVR in Scotland in 1996-2011 were identified using a national 
database. Through record-linkage, we obtained cause-specific mortality data complete to Dec 2013. 
We calculated standardised-mortality-ratios (SMRs) to compare the frequency of mortality in SVR 
patients to the general population. In a parallel analysis, we used Cox regression to identify 
modifiable patient characteristics associated with post-SVR mortality.  
RESULTS: We identified 1824 patients, followed on average for 5.2 years after SVR. In total, 78 
deaths were observed. Overall, all-cause mortality was 1.9 times more frequent for SVR patients than 
the general population (SMR: 1.86; 95% CI:1.49-2.32). Significant cause-specific elevations were 
seen for death due to primary liver cancer (SMR: 23.50; 95% CI:12.23-45.16), and death due to drug-
related causes (SMR: 6.58, 95%CI:4.15-10.45). Together these two causes accounted for 66% of the 
total excess death observed. All of the modifiable characteristics associated with increased mortality 
were markers either of heavy alcohol use or injecting drug use. Individuals without these behavioural 
markers (32.8% of cohort) experienced equivalent survival to the general population (SMR: 0.70; 
95% CI:0.41-1.18) 
CONCLUSIONS:  
Mortality in Scottish SVR patients is higher overall than the general population. The excess was 
driven by death from drug-related causes and liver cancer. Health risk behaviours emerged as 
important modifiable determinants of mortality in this population.  
LAY SUMMARY:  
Patients cured of hepatitis C through treatment had a higher mortality rate overall than the general 
population. Most of the surplus mortality was due to drug-related causes and death from liver cancer. 
A history of heavy alcohol use and injecting drug use were associated with a higher mortality risk. 
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INTRODUCTION:  
The use of direct acting antiviral drugs has led to vast improvements in the efficacy and tolerability of 
treatment for chronic hepatitis C virus (HCV) infection. [1,2] As a result, the number of previously-
infected persons living with a sustained viral response (SVR) is likely to increase rapidly in the years 
ahead. It is important therefore to gain a better understanding of what an SVR means in terms of an 
individual’s subsequent health. SVR is regarded as a “cure” by clinicians[3]; patients[4]; 
pharmaceutical companies [5,6]; and the lay media[7]. Whilst this is accurate in virological terms (i.e. 
SVR does represent a durable eradication of the virus from blood serum[8]), the extent to which SVR 
is a cure for other noted aspects of the hepatitis C condition – namely: liver fibrosis[9], hepatocellular 
carcinoma[10], increased all-cause mortality relative to the general population [11] and extrahepatic 
manifestations[12] - remains unclear. The object of this study was to evaluate the mortality rate aspect 
of this knowledge gap. Although we know that SVR patients have lower mortality rates than non-
SVR patients [3, 13] we do not know how the mortality of this group compares to the general 
population. This is in contrast with other fields of medicine, such as oncology, where comparing 
patient survival against the general population is central to determining rates of cure [14, 15] 
Thus far, only two studies have compared mortality in SVR patients to the general population. The 
first study was based on 192 SVR patients recruited from five tertiary liver clinics in Europe and 
Canada. [16] All patients had advanced fibrosis at baseline and the average age was 49 years. For this 
cohort, ten year survival - at 91.1% - was no different to survival in the general population. More 
recently, Bruno et al examined survival in 181 SVR patients recruited from five clinics in Italy.[17] 
All individuals in this cohort had compensated cirrhosis at baseline, and the average age was 59 years. 
Here too, ten year survival -at 90.9% - was comparable to the general population. These initial data 
are encouraging, nevertheless a question mark remains over how representative their findings are to 
the wider SVR population. Firstly because both studies were confined to patients with advanced 
fibrosis and did not include patients with milder disease (i.e. the group where the greatest burden of 
infection lies [18]). Secondly, because patients in both studies were recruited from potentially select 
clinics that may not be representative –either in terms of the patient case mix or the clinical care 
received – of all clinics administering therapy. Therefore, in this study we analysed mortality data 
from a large nationwide cohort of SVR patients in Scotland. Our objective was to compare cause-
specific mortality in SVR patients to the underlying general population.  
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METHODS: 
1. DATA SOURCES 
1.1:  DATA ON CAUSE-SPECIFIC MORTALITY RATES IN SVR PATIENTS 
We used data from a previously-described [19] retrospective cohort of HCV infected patients treated 
in Scotland who began and terminated a course of interferon-based antiviral therapy between Jan 
1996 and Dec 2010, respectively. This cohort was restricted to patients who were treatment-naïve, and 
who at the time of treatment, had compensated liver disease. It further excluded individuals with HIV 
or hepatitis B co-infection (the latter was inferred on the basis of surface antigen positivity). In total, 
3385 individuals met these criteria of whom 1824 attained SVR and form the focus of this present 
analysis. Subsequent mortality data, specifically information on the date and the cause of death, were 
obtained through record linkage to the Scottish mortality register -see [16] for further details. We 
examined the following seven causes of death; death due to: (i) primary liver cancer, (ii) other liver 
disease (i.e. liver death not due to primary liver cancer), (iii) drug-related causes, (iv) external causes 
(referring mainly to death from accidents, homicide, and suicide), (v) all non-liver cancers, (vi) 
diseases of the circulatory system, (vii) and all other causes not listed above. We used the 
International Classification of Disease (ICD) code present in the underlying cause of death field to 
define these mortality categories; see eTable 1 for further details. Mortality rates were expressed in 
terms of person-years of follow-up. For each individual, we commenced follow-up at 9 months after 
antiviral treatment was stopped (thereby factoring in 6 months for SVR eligibility and a further 3 
month grace period to physically receive the requisite SVR test), and ended follow-up at the date of 
mortality, or the date that our extract of the mortality register was complete until (31 Dec 2013).  
1.2: DATA ON CAUSE-SPECIFIC MORTALITY RATES IN THE GENERAL POPULATION 
We obtained a bespoke dataset from the General Registry Office Scotland of all deaths occurring in 
Scotland between 1996 and 2014, according to the underlying cause of death, the age at death, the 
calendar year of death, and the decedent’s gender. We linked this dataset to mid-year Scottish 
population estimates to determine cause-specific mortality rates for the general population. We 
examined the same seven causes of death as for our SVR cohort and again used the ICD code present 
in the underlying cause of death field to define these categories (see eTable 1).  
2: STATISTICAL ANALYSIS: 
2.1: SURVIVAL IN SVR PATIENTS RELATIVE TO THE GENERAL POPULATION  
2.1.1: TEN YEAR SURVIVAL FUNCTION 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6 
 
We calculated the Kaplan Meier survival function up to ten years after SVR, and juxtaposed this 
against the survival function for the general population according to the equivalent age, sex and 
calendar year distribution.  We generated these curves both in relation to the total cohort (N=1824), 
and also specifically for SVR patients who had not received a diagnosis of cirrhosis at baseline 
(N=1717).Our rationale for focusing on this latter subgroup was that non-cirrhotic SVR patients tend 
to be discharged from clinical care and their liver-related mortality should be low.  
2.1.2: STANDARDISED MORTALITY RATIOS 
The SMR represents the ratio of the number of expected deaths (i.e. expected given general 
population mortality rates) to the number of observed deaths. We determined the standardised 
mortality ratio (SMR) adjusted for age, gender and calendar year. We calculated the SMR for all-
cause mortality, as well as the SMR for each of the seven causes of death listed afore. As per our 
estimates of ten year survival, SMRs were determined both for all SVR patients, and also specifically 
for SVR patients who had not received a diagnosis of cirrhosis at baseline.  
2.2 IDENTIFYING BASELINE FACTORS ASSOCIATED WITH POST-SVR MORTALITY  
We used Cox regression to identify baseline patient characteristics associated with post-SVR 
mortality. The baseline factors we assessed were: (i) age group (<35yrs; 35-49 yrs; and 50yrs+); (ii) 
gender; (iii) diagnosis of liver cirrhosis; (iv) Charlson comorbidity index (CCI); (v) genotype; (vi) 
maximum alcohol consumption sustained for at least six months; (vii) intravenous drug use history; 
(viii) past hospitalisation for alcohol intoxication; (viiii) past hospitalisation for violence-related 
injury; (x) past hospitalisation for drug intoxication; (xi) pre-treatment aspartate aminotransferase-to-
platelet-ratio index(APRI); and (xii) pre-treatment gamma glutamyl transferase(GGT). Diagnosed 
liver cirrhosis refers to whether the patient had been diagnosed with liver cirrhosis by the time of SVR 
attainment. Diagnosis of liver cirrhosis in Scotland over this study period was made through a 
combination of biopsy; transient elastography; abdominal ultrasound; clinical examination; and 
routine liver function tests. Intravenous drug use history and maximum alcohol consumption were 
determined from data self-reported by the patient at the time of their liver clinic assessment. 
Maximum alcohol consumption was specifically defined as the highest level of alcohol use, sustained 
for six months or more, prior to being seen at the HCV treatment clinic. This was categorised as <21 
units/week; 22-49 units/week and ≥50 units/week. Past hospitalisation for alcohol intoxication, 
violence-related injury and drug intoxication were determined from historical hospitalisation records 
dating back to Jan 1980. The ICD codes used to define these events are listed in eTable 2. We 
calculated the CCI to gauge each patient’s comorbidity burden at baseline.[20] The CCI assigns a 
score of 1-6 for each comorbidity present, with a higher score denoting greater severity: A metastatic 
solid tumour, for example, carries a score of 6, renal disease carries a score of 2, whereas 
uncomplicated diabetes incurs a score of 1. The final CCI for an individual is the total of these scores. 
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We used historical hospitalization data dating back to January 1, 1980 to determine the 
presence/absence of the various comorbidities at baseline (as per the ICD codes set out by Quan et al 
[21]). We extracted all liver function tests recorded on the clinical database within 2 years of starting 
treatment. We calculated the mean aspartate aminotransferase level and mean platelet count in order 
to infer the APRI. We categorised APRI as <0.7 and ≥0.7 corresponding to the optimal cut off  to 
distinguish individuals with mild fibrosis (i.e. Metavir F0-F1) from individuals with non-mild fibrosis 
(i.e. Metavir F2+) [22]. We further determined the mean level of GGT, given that this was previously 
found to be an important determinant of SVR attainment in Scotland. [23] Associations between these 
12 baseline factors and all-cause mortality were calculated initially both in their crude unadjusted 
forms, and after adjustment for age group, gender, cirrhosis and CCI. As with our SMR analysis, 
associations were calculated separately both for all SVR patients, as well as specifically for SVR 
patients without a diagnosis of cirrhosis at baseline.   
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RESULTS: 
1: DESCRIPTION OF THE SVR PATIENTS AT BASELINE: 
In this cohort of 1824 SVR patients, the mean age was 40.7 years and most individuals were male 
(67.9%) - see Table.1. The median calendar period at baseline was 2008 (IQR:2006-2010). All 
patients had compensated liver disease. Liver cirrhosis was diagnosed in 5.8%, and 53.6% had an 
APRI score <0.7 (indicative of Metavir F0-F1) where this score was known. In terms of health risk 
behaviours, almost a fifth (18.1%) had a history of heavy alcohol use, and 58.6% reported ever 
injecting drugs. Further, 6.9%, 17.6% and 14.3% had a history of previous hospitalisation due to 
alcohol intoxication, violence-related injury and drug intoxication, respectively. A description of the 
overlap between health risk behaviour variables is provided in eTable 3.     
2: MORTALITY EVENTS OCCURING AFTER SVR: 
The total duration of follow up in our cohort was 10,915 person-years. The mean and median duration 
of follow-up time per patient was 5.2 years and 5.9 years, respectively. In all, 78 deaths were 
observed. Nine deaths were due to primary liver cancer (eight deaths of which were cases of 
hepatocellular carcinoma, and one was a case of intrahepatic bile duct cancer); seven deaths were due 
to other liver-related causes; 18 deaths were drug-related; 5 deaths were due to external causes; 16 
deaths were from non liver cancers; 9 deaths were due to diseases of the circulatory system; and the 
remaining 14 deaths were from other causes. To note, lung cancer was the most common type of non-
liver cancer death (N=7), whilst chronic obstructive pulmonary disease was the most common type of 
“other” death (N=4). Finally, the nine deaths from primary liver cancer occurred after a mean of 4.8 
years of follow-up at ages ranging from 46-77 years.  
3: SURVIVAL IN SVR PATIENTS RELATIVE TO THE GENERAL POPULATION  
3.1: TEN YEAR SURVIVAL FUNCTION 
For all SVR patients, ten year survival was 93.2% (95% Cl: 91.2%-84.8%) versus 96.1% for the 
general population. For SVR patients without baseline cirrhosis, ten year survival was 94.6% (95% 
CI: 92.7 96.1), versus 96.3% for the general population (Fig.1).   
3.2: ALL-CAUSE AND CAUSE-SPECIFIC STANDARDISED MORTALITY RATIOS: 
The number of all-cause deaths that would have been expected in our SVR cohort given general 
population mortality rates was 42. Thus with 78 deaths actually observed, the overall SMR was 1.86 
(95% CI: 1.49-2.32). When confining the analysis to patients that had not been diagnosed with liver 
cirrhosis at baseline, the SMR fell to 1.55 (95% CI: 1.20-2.01). In terms of cause-specific SMRs (see 
Table 2.), significant elevations were observed for death due to primary liver cancer and death due to 
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drug-related causes. The SMR for liver cancer was less pronounced in the subgroup of patients 
without diagnosed cirrhosis at baseline (SMR: 9.02; 95% CI: 2.91-27.96), than in the entire SVR 
cohort as a whole (SMR: 23.50; 95% CI: 12.23-45.16). In contrast, the SMR for drug related mortality 
was comparable between all SVR patients (SMR: 6.58, 95% CI: 4.15-10.45), and SVR patients 
without baseline cirrhosis (SMR: 6.90, 95% CI: 4.35-10.96).  We did not see any statistically 
significant differences in the SMRs for liver cancer mortality, all-cause mortality and drug mortality 
according to age (see Figure 3[i]). Finally, no statistically significant elevations were noted for the 
remaining cause-specific categories, including: other liver disease; external causes, diseases of the 
circulatory system; and non-liver cancers.  
4: THE ABSOLUTE CONTRIBUTION OF EACH CAUSE TO THE OVERALL EXCESS:  
Drug-related mortality made the biggest absolute contribution to overall excess mortality (42% in all 
SVR patients, and 75% in SVR patients without baseline cirrhosis). Primary liver cancer accounted 
for 24% of the total excess in all SVR patients and 13% of the excess in SVR patients without 
cirrhosis. Taken together, these two causes of death accounted for 66% of all excess deaths in the 
SVR cohort as a whole, and 88% of all excess death in SVR patients without cirrhosis (see Fig.2). We 
further examined the absolute contribution of primary liver cancer and drug-related mortality in all 
SVR patients according to age during follow-up (see Figure 3[ii]). In the under 50s, drug-related 
causes accounted for the majority of the excess death (53%), whilst the contribution of primary liver 
cancer was minimal (<5%). Conversely, in the over 50s, most of the excess (54%) was due to liver 
cancer, whilst drug-related mortality played a more minor role (accounting for only 26% of the 
excess).  
5: BASELINE FACTORS ASSOCIATED WITH ALL-CAUSE MORTALITY 
Ten factors were significantly associated (p<0.05) with an increased risk of post-SVR mortality 
following adjustment for age group and gender, cirrhosis and CCI; see Table.1. These were as 
follows: older age; male gender; diagnosis of liver cirrhosis; high Charlson comorbidity score; past 
alcohol consumption ≥50+ units/wk sustained for six months or more; history of intravenous drug 
use; past hospitalisation for alcohol intoxication; past hospitalisation for drug intoxication; and past 
hospitalisation for violence-related injury, and APRI <0.7. 
6: POST-HOC ANALYSES: GENERATING A COMPOSITE SCORE FOR HEALTH RISK 
BEHAVIOURS 
The five modifiable factors associated with post-SVR mortality were as follows: 1. past alcohol 
consumption ≥50+ units/wk sustained for six months or more; 2. history of intravenous drug use; 3. 
past hospitalisation for alcohol intoxication; 4. past hospitalisation for drug intoxication; and 5.past 
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hospitalisation for violence-related injury heavy alcohol use). In a post-hoc analysis, we generated a 
4-point composite score based on the presence or absence of these five factors (see Fig.4). The 
intention was to create a proxy marker for health risk behaviours present during follow-up. We 
calculated SMRs for all-cause mortality according to this composite score and observed a strong dose-
response relationship (p-value for trend, <0.001). Among all SVR patients with a score of zero (i.e. 
indicating the minimum level of health risk behaviour), the SMR was 0.70 (95% CI: 0.41-1.18), 
whereas for individuals with a score of 3 (i.e. the maximum score, indicating the highest level of 
health risk behaviour), the SMR was 6.19 (95% CI: 3.60-10.67). We also constructed a multivariate 
Cox regression model to assess the association between our behaviour score and the mortality hazard 
after adjusting for age, sex, cirrhosis, CCI and APRI (see Table 3). We observed a stepwise change in 
the mortality hazard according to behaviour score. Among all SVR patients, the hazard was 2.12 
times (p=0.035) , 4.25 times (p<0.001), and 7.28 times (p<0.001) higher for individuals with a score 
of 1, 2 and 3, respectively, relative to individuals with a score of zero.  
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DISCUSSION: 
MAIN FINDINGS:  
The arrival of highly effective and tolerable antiviral regimens for chronic hepatitis C infection has set 
the stage for a rapid increase in the number of persons living with SVR. Yet, our present 
understanding of the prognosis that this “cured” population face is incomplete. Although we know 
that SVR patients exhibit superior mortality and morbidity rates relative to non-SVR patients [3, 13, 
18], we know little about how these rates compare to the broader general population. In the present 
study, we followed 1824 SVR patients up for 5.2 years on average, and observed mortality rates in 
excess of the general population.  Specifically, among all SVR patients, mortality rates were almost 2-
fold higher (SMR: 1.86; 95% CI: 1.49-2.32), whilst among SVR patients without a diagnosis of 
cirrhosis at baseline - a group who on the whole will tend to be discharged from specialist care 
without further follow-up - mortality rates were 1.6-fold higher (SMR: 1.55; 95% CI:1.20-2.01) .  Our 
cause-specific analyses (see Table 2 and Fig.2-3) demonstrated two important points. Firstly, that the 
overall excess was driven, in the main, by a higher than expected frequency of death from liver cancer 
and death from drug-related causes. Secondly, that the contribution of these two causes differed with 
respect to age. Drug-related mortality accounted for 53% of all excess death in the under 50s (in 
comparison, only 4.3% of the excess death was due to primary liver cancer). Conversely, death from 
liver cancer accounted for 54% of all excess death in the over 50s (whereas, in this age group, only 
26% of the excess death was due to drug-related causes).  
THE OCCURRENCE OF PRIMARY LIVER CANCER: 
The largest cause-specific SMRs were seen with respect to primary liver cancer. In our SVR cohort as 
a whole, the risk of dying from liver cancer was more than 20 times greater than the general 
population (SMR: 23.50; 95% CI: 12.23-45.16). Notably, an excess risk of dying from liver cancer 
remained - SMR: 9.02; 95% CI: 2.91-27.96 - after excluding individuals with diagnosed liver 
cirrhosis at baseline. This result requires careful interpretation. On the one hand, it could lend support 
to previous observations that the risk of liver cancer after SVR is not confined to cirrhotic patients, 
but extends more widely to some patients at the pre-cirrhosis stage.[24-28] Alternatively, it may 
reflect a high level of undiagnosed liver cirrhosis in our cohort (indeed, the potential for this is 
appreciable, given that the majority of patients had no record of a liver biopsy or fibroscan being 
conducted  in the two years prior to baseline – see eTable 4). To inform which interpretation is more 
valid, we reviewed the medical notes of the three “non cirrhotic” individuals who went on to develop 
primary liver cancer (involving two deaths from hepatocellular carcinoma and one from intrahepatic 
bile duct carcinoma). While two patients had indications of significant/severe fibrosis, none of the 
three would have met the definition of compensated cirrhosis currently adopted by NHS England (see 
Appendix A), despite all having the requisite tests to do so on at least one level (i.e. all three had an 
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APRI score and AST:ALT ratio pre-treatment; while one case had an ultrasound and another had a 
biopsy upon completion of therapy). Further, only one case was retained in on-going clinical follow-
up post SVR, while the other two were discharged. More research is arguably needed to inform which 
SVR patients can be safely discharged, versus which patients would benefit from regular HCC 
screening. However, we must stress that although the relative risk of a liver cancer death was high in 
the non-cirrhotic group (i.e.  nine times higher relative to the general population), the absolute risk – 
both of liver cancer and indeed of any liver-related event - was still very low (<1% after 7.5 years - 
see eFig.1).  
PATIENT CHARACTERISTICS ASSOCIATED WITH POST-SVR MORTALITY: 
To understand how the elevated mortality rate in “cured” hepatitis C patients might be reversed, we 
carried out a regression analysis to identify modifiable predictors of all-cause mortality (see Table.1). 
Ten predictive characteristics were identified in total, of which half – older age, male gender, liver 
cirrhosis; high CCI; and APRI <0.7 – were non-modifiable. But the remaining characteristics 
identified were markers of health risk behaviours (history of injecting drug use, history of heavy 
alcohol use, and past hospitalisation for violence, drug intoxication or alcohol intoxication) that, in 
principle at least, can be reversed. We created a composite score to approximate the degree of health 
risk behaviours present during follow-up (see Fig.4). The strong correlation between this composite 
score and the all-cause SMR suggests two things. Firstly, that health risk behaviours exert a strong 
influence on the extent to which mortality exceeds general population levels. Secondly, where health 
risk behaviours are minimal (i.e. as indicated by a score of zero) all-cause mortality rates are 
equivalent to and even lower than the general population.  
From the non-modifiable predictors identified in this study, the increased mortality risk associated 
with APRI <0.7 (versus APRI ≥0.7) was unexpected and at first glance paradoxical – see Table 1. 
Subsequent interrogation revealed however that this association was very cause-specific, being driven 
only by an increased risk for drug mortality (see eFig.2). The association overall therefore is probably 
due to residual confounding. Mild disease will be associated with more recent acquisition of HCV 
(given that fibrosis increases with duration of infection), which in turn will be associated with active 
drug use. With more robust data on active drug use at baseline, we would therefore not expect an 
association with APRI<0.7 to persist. 
CONSISTENCY WITH PREVIOUS WORK: 
Our finding of higher mortality in SVR patients relative to the general population is not supported by 
two previous studies. In a cohort of 192 SVR patients with F3-F4 fibrosis and an average age of 49 
years, Van der Meer et al observed a 10-year survival rate of 91.1%. [17] This was on par with 
survival in the general population. More recently, Bruno et al reported 10 year survival of 90.9% for 
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177 SVR cirrhotic patients with a mean age of 59 years. [18] Again, this 10-year survival was 
comparable to the general population. In contrast, for the present study, we followed up a much larger 
(N=1824), younger (mean age of 40.7 yrs) and more inclusive (comprising patients across the fibrosis 
continuum – not just those at an advanced end) group of SVR patients. Conversely, the 10-year 
survival that we observed of 93.2% was significantly lower than the 96.2% survival expected for the 
general population taking age, sex and calendar period into account. In overall terms, 86% more 
deaths were observed during our study than would have been expected under general population 
mortality rates (i.e. 78 deaths observed versus 42 expected). One possible explanation for the higher 
mortality rate in our study could be selection bias. The patients in our Scottish cohort represent the 
vast majority (80%+)  of individuals attaining SVR in Scotland over the 1996-2011 time frame of this 
study. In contrast, the two previous studies were largely made up of individuals with biopsy-proven 
advanced liver fibrosis that attended a small number of tertiary clinics that may not accurately reflect 
the wider SVR population. Clearly more studies, from a variety of cohorts, are required to form a 
complete picture on this issue. Otherwise, our results concur with a prior analysis from Scotland 
reporting increased hospitalisation rates in SVR patients relative to the general population [29]. Our 
results are also consistent with a nationwide cohort study from Denmark. [30] In this study, Omland 
et al observed that individuals who clear HCV infection spontaneously (not via treatment albeit) had 
higher overall mortality than the general population. However, - in line with this study (see fig.4) - 
mortality was more comparable to the general population in subgroups without a history of alcohol 
and drug abuse.   
LIMITATIONS OF THIS STUDY: 
There are several limitations in this analysis to highlight. Cirrhosis was diagnosed in only 5.8% of 
patients at baseline, however due to inadequate testing, this is likely to be an underestimate of the true 
fraction with cirrhosis. Indeed, e-Table 4 shows that only 44% of patients received a liver biopsy or a 
fibroscan in the two years prior to SVR attainment, which highlights the lack of uniform cirrhosis 
surveillance in our cohort. Potentially, undiagnosed liver cirrhosis could explain why we observed six 
liver deaths in our non-cirrhotic group, albeit we think that this is unlikely because when we reviewed 
the medical notes of the 3 “non-cirrhotic” patients who developed liver cancer, we did not find 
anything to suggest that these individuals were cirrhotic in reality. Another limitation is that we had 
no information on the socioeconomic status of patients in this cohort. Because hepatitis C virus 
infection disproportionately affects people of lower socioeconomic status, and lower socioeconomic 
status is in turn associated with higher mortality rates [31], the omission of this variable could have 
inflated our survival differences. Thirdly, our data on health risk behaviours are limited in that they 
relate only to the baseline time point, and mostly focus on only the extremes of alcohol and drug use. 
Future studies correcting for these weaknesses and additionally examining the impact of other major 
health behaviours –tobacco smoking, physical activity and diet—would be valuable. Fourthly, 
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patients in our cohort were treated with either standard interferon ± ribavirin, or pegylated interferon ± 
ribavirin. These regimens are long (16-48 weeks) and entail significant adverse effects. As a result, 
patients would typically have received intensive coaching from clinicians and nursing staff (and this 
coaching would have applied especially to SVR patients who, given futility stopping rules, remain in 
the treatment window for longer than non-SVR patients). We have previously speculated that this 
coaching and/or the euphoria of attaining SVR may have an important galvanising effect on patients 
with regard to encouraging more salubrious health behaviours [19]. Thus, in the impending era of 
highly tolerable, accessible and efficacious antiviral therapy– i.e. an era that will obviate the same 
level of patient coaching and patient commitment – a very different post-SVR picture could emerge. It 
will be important to repeat this analysis five years hence. Finally, we did not have robust data on 
diabetes mellitus status and obesity despite these conditions being recognised determinants of liver 
sequelae in the SVR population.[32] 
SUMMARY: 
In this large nationwide Scottish cohort, mortality in patients with a hepatitis C “cure” was higher than 
the general population.  The excess was mainly driven by death from liver cancer and death from 
drug-related causes. Health risk behaviours emerged as the major modifiable risk factor for mortality 
in this population underlining the importance of a multidisciplinary approach to HCV that addresses 
lifestyle risk factors in addition to viral infection. On this note the SVR time-point may be a 
particularly opportune moment to assess what other services and support the patient may be in need 
of. To minimise the post-SVR risk of HCC, careful and prudent staging of liver fibrosis should be 
performed prior to discharge to identify those patients who might benefit from regular screening. 
Arguably, more research is needed to bottom out more precisely which SVR patients stand to benefit 
from such surveillance. As a final aside, this analysis has bearing on the new WHO targets to cut 
global death from hepatitis B and C by 10% before 2020, and by 65% by 2030 [33].  
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FIGURE LEGENDS:  
Fig.1: Ten-year survival relative to the general population for: (i) all SVR patients; and (ii) SVR 
patients without cirrhosis. 
Fig.2: Absolute contribution (%) to the overall excess for each cause of death, for (i) all SVR patients, 
and (ii) SVR patients without cirrhosis at baseline. 
Fig.3: For all SVR patients: (i) cause-specific standardised mortality ratios according to age, and (ii) 
absolute contribution (%) to the overall excess for each cause of death, according to age. 
Fig.4: Standardised mortality ratio according to baseline health risk behaviours, for (i) all SVR 
patients, and (ii) SVR patients without cirrhosis.  
 
 Number (col %) Deaths Crude hazard ratio (95 
% CI)
Adjusted hazard ratio 
(95 % CI) †
Number (col %) Deaths Crude hazard ratio (95 
% CI)
Adjusted hazard ratio 
(95 % CI)‡
<35 yrs 542 (29.7) 11 REF (1.00) REF (1.00) 538 (31.3) 11 REF (1.00) REF (1.00)
35-49yrs 976 (53.5) 41 2.14 (1.10-4.16)* 1.79 (0.91-3.54) 922 (53.7) 33 1.82 (0.92-3.61) 1.73 (0.87-3.46)
50+yrs 306 (16.8) 26 4.28 (2.11-8.68)*** 2.76 (1.31-5.84)** 257 (15.0) 14 2.74 (1.24-6.06)* 2.55 (1.15-5.69)*
Female 585 (32.1) 12 REF (1.00) REF (1.00) 556 (32.4) 10 REF (1.00) REF (1.00)
Male 1239 (67.9) 66 2.75 (1.49-5.09)** 2.58 (1.39-4.79** 1161 (67.6) 48 2.45 (1.24-4.85)* 2.44 (1.23-4.82)*
No 1717 (94.1) 58 REF (1.00) REF (1.00) 1717 (100.0) 58 \ \
Yes 107 (5.9) 20 5.34 (3.21-8.89)*** 3.11 (1.72-5.60)*** 0 (0.0) 0 \ \
None (0) 993 (54.4) 30 REF (1.00) REF (1.00) 966 (56.3) 27 REF (1.00) REF (1.00)
Medium (1-2) 758 (41.6) 35 1.04 (0.64-1.72) 0.87 (0.53-1.45) 704 (41.0) 26 0.92 (0.53-1.60) 0.85 (0.49-1.48)
High (3+) 73 (4.0) 13 5.27 (2.75-10.13)*** 2.35 (1.13-4.90)* 47 (2.7) 5 3.33 (1.28-8.68)* 2.84 (1.08-7.45)*
non-3 612 (33.6) 27 REF (1.00) REF (1.00) 582 (33.9) 22 REF (1.00) REF (1.00)
3 1130 (62.0) 44 0.80 (0.50-1.30) 0.77 (0.47-1.25) 1057 (61.6) 30 0.69 (0.40-1.20) 0.73 (0.42-1.28)
Missing 82 (4.5) 7 0.88 (0.37-2.10) 0.99 (0.41-2.37) 78 (4.5) 6 0.97 (0.38-2.50) 1.04 (0.40-2.67)
<21 1378 (75.6) 45 REF (1.00) REF (1.00) 1321 (76.9) 39 REF (1.00) REF (1.00)
22-49 116 (6.4) 4 0.93 (0.33-2.58) 0.66 (0.23-1.86) 107 (6.2) 2 0.57 (0.14-2.35) 0.49 (0.12-2.06)
50+ 330 (18.1) 29 3.02 (1.89-4.82)*** 2.12 (1.30-3.47)** 289 (16.8) 17 2.25 (1.27-3.99)** 1.91 (1.07-3.43)*
No 756 (41.5) 25 REF (1.00) REF (1.00) 703 (40.9) 12 REF (1.00) REF (1.00)
Yes 1068 (58.6) 53 1.75 (1.09-2.82)* 2.36 (1.41-3.94)** 1014 (59.1) 46 3.14 (1.66-5.94)*** 3.41 (1.77-6.56)***
No 1699 (93.2) 65 REF (1.00) REF (1.00) 1604 (93.4) 48 REF (1.00) REF (1.00)
Yes 125 (6.9) 13 3.25 (1.79-5.90)*** 3.17 (1.72-5.85)*** 113 (6.6) 10 3.49 (1.76-6.91)*** 3.42 (1.71-6.82)***
No 1503 (82.4) 58 REF (1.00) REF (1.00) 1415 (82.4) 43 REF (1.00) REF (1.00)
Yes 321 (17.6) 20 2.01 (1.21-3.35)** 1.88 (1.10-3.20)* 302 (17.6) 15 2.05 (1.14-3.71)* 1.84 (1.00-3.40)*
No 1563 (85.7) 58 REF (1.00) REF (1.00) 1468 (85.5) 39 REF(1.00) REF (1.00)
Yes 261 (14.3) 20 2.34 (1.41-3.90)** 2.87 (1.68-4.89)*** 249 (14.5) 19 3.26 (1.88-5.65)*** 3.59 (2.01-6.41)***
<0.7 (~mild fibrosis) 639 (35.0) 24 REF (1.00) REF (1.00) 632 (36.8) 22 REF (1.00) REF (1.00)
≥0.7 (~ non-mild fibrosis) 553 (30.3) 21 0.85 (0.47-1.52) 0.50 (0.27-0.94)* 496 (28.9) 12 0.58 (0.29-1.18) 0.51 (0.25-1.03)*
Missing 632 (34.7) 33 1.11 (0.66-1.89) 0.76 (0.43-1.32) 589 (34.3) 24 0.96 (0.53-1.71) 0.87 (0.48-1.57)
<55 933 (51.2) 26 REF (1.00) REF (1.00) 913 (53.2) 24 REF (1.00) REF (1.00)
≥55 610 (33.4) 33 2.16 (1.29-3.62)** 1.30 (0.76-2.24) 536 (31.2) 18 1.41 (0.76-2.59) 1.13 (0.61-2.09)
Missing 281 (15.4) 19 2.17 (1.20-3.95)* 1.68 (0.92-3.09) 268 (15.6) 16 2.03 (1.07-3.84)* 1.78 (0.93-3.38)
Basic demographics (i) Age group
(ii) Gender
TABLE 1: Baseline characteristics associated with post-SVR mortality, for: (I) all SVR patients; and (II) SVR patients without cirrhosis at baseline
Category Variable
(I) ALL SVR PATIENTS; (N=1824) (II) SVR PATIENTS WITHOUT BASELINE CIRRHOSIS; (N=1717)
Medical co-
morbidities
(iii) Diagnosed with cirrhosis
(iv) Charlson co-morbidity 
index
Viral genotype (v) Genotype
** denotes p-value <0.01
*** denotes p-value <0.001
(x) Past hospitalisation for 
drug intoxication
Liver Function Tests (xi) Mean aspartate 
aminotransferase-to-platelet 
ratio-index 
(xii) Mean Gamma-Glutamyl 
Transferase before treatment 
(IU/l) 
* denotes p-value ≤0.05
Health risk behaviours (vi) Maximum units/wk 
alcohol sustained for at least 
six months
(vii) History of intravenous 
drug use
(viii) Past hospitalisation for 
alcohol intoxication
(viiii) Past hospitalisation for 
violence-related injury
† multivariate adjustment for : 1. age group ; 2. gender, 3. Charlson Comorbidity Index, 4. liver cirrhosis 
‡ multivariate adjustment for : 1. age group ; 2. gender, 3. Charlson Comorbidity Index
Table
  
 
 
 
 
 
 
  
 
Adjusted hazard ratio 
(95 % CI)
p-value Adjusted hazard ratio 
(95 % CI)
p-value
REF (1.00) \ REF (1.00) \
2.12 (1.05-4.25) 0.035 3.74 (1.47-9.57) 0.006
4.25 (2.15-8.41) <0.001 7.22 (2.89-18.05) <0.001
7.28 (3.29-16.08) <0.001 10.42 (3.54-30.68) <0.001
<35 yrs REF (1.00) \ REF (1.00) \
35-49yrs 1.60 (0.81-3.18) 0.177 1.58 (0.46-1.49) 0.197
50+yrs 3.80 (1.80-8.01) <0.001 3.32 (1.48-7.46) 0.004
Female REF (1.00) \ REF (1.00) \
Male 2.11 (1.12-3.94) 0.020 1.82 (0.91-3.64) 0.089
No REF (1.00) \ \ \
Yes 3.31 (1.81-6.02) <0.001 \ \
None (0) REF (1.00) \ REF (1.00) \
Medium (1-2) 0.88 (0.52-1.46) 0.614 0.89 (0.51-1.55) 0.67
High (3+) 3.01 (1.44-6.26) 0.003 3.45 (1.31-9.09) 0.012
<0.7 (mild fibrosis) REF (1.00) \ REF (1.00) \
≥0.7 (non-mild fibrosis) 0.49 (0.26-0.92) 0.025 0.50 (0.25-1.02) 0.058
Missing 0.73 (0.42-1.27) 0.269 0.83 (0.46-1.49) 0.525
(I) All SVR patients (N=1824) (II) SVR patients without 
cirrhosis (N=1717)
Table 3: Multivariate model including health risk behaviour composite score, for (i)all SVR patients (N=1824); (ii) SVR 
patients without cirrhosis (N=1717).
Category Variable
Liver Function Tests (xi) Mean aspartate 
aminotransferase-to-platelet 
ratio-index
Medical co-
morbidities
(iii) Diagnosed with cirrhosis
(iv) Charlson co-morbidity 
index
Basic demographics (i) Age group
(ii) Gender
Composite health risk 
behaviour score
0 (most favourable)
1
2
3 (least favourable)
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Patients not diagnosed with 
cirrhosis (N=1717) 
58 deaths 
observed 
37 deaths 
expected* 
Standardised Mortality Ratio: 58/37 
= 1.55 (95% CI: 1.20-2.01) 
Mortality in a nationwide cohort of SVR 
patients relative to the general population 
All patients (N=1824) 
* Expected on the basis of age, sex and calendar year adjusted mortality rates of the general Scottish population 
78 deaths 
observed 
42 deaths 
expected* 
Standardised Mortality Ratio: 78/42 
= 1.86 (95% CI: 1.49-2.32) 
*Graphical Abstract
